Global Non Invasive Prenatal Testing Market is set to grow at a healthy CAGR of 16% to reach $9 billion by 2026 - Rising Prevalence of Genetic and Congenital Disorders

Non-invasive prenatal testing (NIPT), is a method of determining the risk of whether the fetus of the mother will be born with certain genetic abnormalities. NIPT is a highly safe and effective way of screening for abnormal conditions such as Down syndrome, Edwards syndrome, Patau syndrome, monosomy X, and Turner syndrome.

Currently, there are two types of NIPT methods which are available, massive parallel sequencing (MPS) technology and the single-nucleotide polymorphism (SNP) based method.

Growing Shift towards Cell-Free DNA screening

The Discovery of cell-free DNA (cfDNA)-based NIPT has created a rapid shift in the paradigm of aneuploidy screening during pregnancy. It's a simple blood test which can be performed during pregnancy. Clinical validation studies suggest that NIPT is more accurate than combined first-trimester screening (CFTS), with very high sensitivity (99.3%) and specificity (99.9%) for trisomy 21(Down syndrome). NIPT is also safer than other invasive diagnostic techniques such as chorionic villus sampling and amniocentesis, which involves a risk of miscarriage (0.1-0.2%).

Development of Advanced Medical Technologies for NIPT Products

The development of next-generation sequencing technology has enabled the sequencing of fetal DNA fragments which can be assembled into a full genetic map, allowing the fetal genome to be scanned prenatally and non-invasively. Developments in molecular technologies and the discovery of cell-free fetal DNA in maternal plasma have also led to novel screening methods for fetal chromosomal aneuploidies.

Currently, various types of NIPT tests are available in the market such as Panorama, Vistara, MaterniT GENOME, Harmony Test, among others which help in the screening of chromosomal abnormalities developing in the fetus. Moreover, several and recent developments have been made to impact the quality of care for expectant mothers such as:

• In January 2022, QIAGEN entered into collaborations with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN's dPCR franchise.
• In June 2021, Illumina and Next-generation Genomic Thailand announced the launch of next-generation sequencing (NGS)-based VeriSeq NIPT Solution v2 in the country which helps to detect anomalies missed by targeted assays.

"Prenatal care is a dynamic and continuously evolving field. Development in new molecular technologies and the discovery of cell-free fetal DNA are fueling groundbreaking advancements to improve care for mother and child and to offer parents reproductive options."-Senior Director, Head of R&D Department, Sequencing & Array-based Company, USA

Key Market Challenges: Non Invasive Prenatal Testing Market

Some of the major challenges restricting the growth of the global non invasive prenatal testing market are stringent government regulations, and limitations of NIPT such as despite its high accuracy, it is still considered a screening test.

Geographic Analysis: North America is the Largest Non Invasive Prenatal Testing Market

North America is the largest non invasive prenatal testing market with >45% revenue share, followed by Europe. The increasing prevalence of genetic disorders in newborns associated with growing maternal age, wider adoption, and the presence of major players working on fetal and neonatal care in this region are some of the primary factors driving the North America market. The non invasive prenatal testing market in Europe is expected to grow rapidly over the forecast period due to the adoption of the latest technologies, new product launches, and a strong reimbursement framework for these tests in this regions. The Asia Pacific region is expected to witness the highest growth in the upcoming years.

Competitive Landscape Analysis: Non Invasive Prenatal Testing Market

Some of the established players operating in the global non invasive prenatal testing market are Agilent Technologies, BGI Genomics, Cradle Genomics, Berry Genomics, Sequenom, Roche (Ariosa Diagnostics), etc.

Get Detailed Insights on Non Invasive Prenatal Testing Market with Report TOC @ https://meditechinsights.com/non-invasive-prenatal-testing-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.